India's Dr. Reddy's Laboratories Buys U.K. Dow Chemical Drug Units To Bolster Contract Research
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - India's second biggest generic drug firm, Reddy's Laboratories, bought two small molecule plants from a U.K. unit of Dow Chemical as part of a drive to gain technology to expand its contract manufacturing business
You may also be interested in...
Dr Reddy’s Earnings Plunge On German Unit Charge, Increased Generic Competition
NEW DELHI - Dr Reddy's Laboratories, India's second-biggest drugmaker, said third quarter earnings and revenues plunged on lower-than-expected earnings in Germany and increased competition as it changes its mix of generic drug products
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
Need a specific report? 1000+ reports available
Buy Reports